Therapeutic CD8 <sup>+</sup> T cell tissue retention and immunomodulation during ART interruption fail to prevent SIV rebound
Abstract
A primary obstacle for HIV elimination is the long-term viral reservoir in lymphoid tissues (LT) that can cause rebound viremia if therapy is stopped. Cytotoxic CD8 + T cells are critical for control of HIV and Simian immunodeficiency virus (SIV) viremia; however, CD8 + T cells that migrate to LT are primarily noncytotoxic, calling into question whether these cells could reduce the viral reservoir on antiretroviral therapy (ART) or control viral replication when therapy is halted. To determine whether CD8 + T cells can inhibit viral replication when retained in LT, we inhibited lymphocyte egress from LTs in ART-treated SIV-infected rhesus macaques (RMs) during analytic treatment interruption (ATI) using the S1PR modulator FTY720 alone or in combination with anti-PD1 antibody (αPD1) and the IL-15 receptor superagonist N-803 to increase cytolytic function. FTY720 retained migrating CD4 + and CD8 + T cells in LT, whereas cytotoxic CD8 + T cells remained in the vasculature. After ATI and viral rebound, activated SIV-specific CD8 + T cells increased in frequency in LT of FTY720-treated RMs but failed to become cytotoxic or control plasma viremia compared to controls, even when combined with αPD1 and N-803. These findings indicate that LT-localized CD8 + T cells alone may be insufficient to delay or prevent plasma viral rebound during ATI.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (15)
M. Betina Pampena
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania
Sadia Samer
Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
Elise G. Viox
Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
Kevin Nguyen
Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
Claire Deleage
AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc.
Leticia Kuri-Cervantes
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania
James Regan
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania
Vincent H. Wu
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania
Steffen Docken
Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales
Jeffrey T. Safrit
ImmunityBio, Inc.
Katharine J. Bar
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania
Brandon F. Keele
Miles P. Davenport
Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales
Mirko Paiardini
Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
Michael R. Betts
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania